Spots Global Cancer Trial Database for braf v600e mutation present
Every month we try and update this database with for braf v600e mutation present cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02097225 | BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So... | Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | NCT03224767 | BRAF V600E Muta... Papillary Crani... | Vemurafenib Cobimetinib Laboratory Biom... Quality-of-Life... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | NCT04061980 | BRAF NP_004324.... BRAF V600E Muta... Metastatic Thyr... Refractory Thyr... Stage IV Differ... Stage IVA Diffe... Stage IVB Diffe... | Binimetinib Encorafenib Nivolumab | 18 Years - | Providence Health & Services | |
| Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | NCT03224767 | BRAF V600E Muta... Papillary Crani... | Vemurafenib Cobimetinib Laboratory Biom... Quality-of-Life... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | NCT04061980 | BRAF NP_004324.... BRAF V600E Muta... Metastatic Thyr... Refractory Thyr... Stage IV Differ... Stage IVA Diffe... Stage IVB Diffe... | Binimetinib Encorafenib Nivolumab | 18 Years - | Providence Health & Services | |
| Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | NCT01940809 | BRAF V600E Muta... BRAF V600K Muta... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Dabrafenib Ipilimumab Laboratory Biom... Nivolumab Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02097225 | BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So... | Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
